ÂÜÀòÂÒÂ×

David Lubner is a seasoned professional in the biopharmaceutical sector, currently serving as a member of the Board of Directors for multiple companies, including CARGO Therapeutics, Arcellx, Inc., Be Biopharma, Cerevance, Vor Biopharma, Ichnos Sciences, Dyne Therapeutics, and POINT Biopharma, the latter of which was acquired by Eli Lilly and Company. Lubner's prior affiliations include serving on the Board of Directors for Gemini Therapeutics until its merger with Disc Medicine and for Therapeutics Acquisition Corp., which completed a merger with Point Biopharma. Educationally, Lubner holds a Bachelor of Science in Accounting and Business/Management from Northeastern University and a Master's in Taxation from Bentley University.